Serum calcitonin response to induced hypercalcemia

Area of Science:

• Endocrinology
• Oncology
• Diagnostic Medicine

Background:

• Medullary thyroid carcinoma (MCT) diagnosis relies on serum calcitonin (S-CT).
• Sipple's syndrome is a hereditary condition associated with MCT.
• Early detection of occult MCT is crucial for effective management.

Purpose of the Study:

• To evaluate the efficacy of a calcium infusion test for diagnosing medullary thyroid carcinoma (MCT).
• To assess the sensitivity of the delta-CT240 (rise in serum calcitonin 240 minutes post-infusion) in detecting early or occult MCT.
• To compare the diagnostic utility of the calcium infusion test with basal S-CT levels.

Main Methods:

• A prospective screening study involving patients with Sipple's syndrome, sporadic MCT cases, and healthy controls.
• Induction of hypercalcemia via intravenous calcium gluconate infusion.
• Measurement of serum calcitonin levels before and 240 minutes after calcium infusion (delta-CT240).

Main Results:

• The calcium infusion test demonstrated no false negatives in 14 confirmed MCT patients.
• Basal S-CT levels were already indicative of MCT in these patients.
• In relatives of Sipple's syndrome patients, the delta-CT240 test identified 5 borderline cases not clearly distinguished by basal S-CT, suggesting earlier detection of occult MCT.
• The test showed normal results in healthy controls and patients with chronic hypocalcemia.

Conclusions:

• The calcium infusion test is a highly sensitive method for the early diagnosis of occult medullary thyroid carcinoma.
• It is recommended for screening Sipple relatives, postoperative monitoring of MCT patients, and investigating tumors with potential calcitonin production.
• The delta-CT240 measurement offers superior sensitivity for detecting subtle forms of MCT compared to basal S-CT levels.